530 related articles for article (PubMed ID: 34779844)
21. Patient Out-of-Pocket Costs for Biologic Drugs After Biosimilar Competition.
Feng K; Russo M; Maini L; Kesselheim AS; Rome BN
JAMA Health Forum; 2024 Mar; 5(3):e235429. PubMed ID: 38551589
[TBL] [Abstract][Full Text] [Related]
22. Trends in Use and Expenditures for Brand-name Statins After Introduction of Generic Statins in the US, 2002-2018.
Lin SY; Baumann K; Zhou C; Zhou W; Cuellar AE; Xue H
JAMA Netw Open; 2021 Nov; 4(11):e2135371. PubMed ID: 34807258
[TBL] [Abstract][Full Text] [Related]
23. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
Li DG; Joyce C; Mostaghimi A
JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
[TBL] [Abstract][Full Text] [Related]
24. Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012-2018.
Rome BN; Lee CC; Kesselheim AS
Clin Pharmacol Ther; 2021 Feb; 109(2):367-371. PubMed ID: 32654122
[TBL] [Abstract][Full Text] [Related]
25. Using Multiple Authorized Generics to Maintain High Prices: The Example of Entacapone.
Rome BN; Egilman AC; Patel NG; Kesselheim AS
Value Health; 2023 Mar; 26(3):370-377. PubMed ID: 36266218
[TBL] [Abstract][Full Text] [Related]
26. Projected US savings from biosimilars, 2021-2025.
Mulcahy A; Buttorff C; Finegold K; El-Kilani Z; Oliver JF; Murphy S; Jessup A
Am J Manag Care; 2022 Jul; 28(7):329-335. PubMed ID: 35852882
[TBL] [Abstract][Full Text] [Related]
27. Effect of Competition on Generic Drug Prices.
Nguyen NX; Sheingold SH; Tarazi W; Bosworth A
Appl Health Econ Health Policy; 2022 Mar; 20(2):243-253. PubMed ID: 34904207
[TBL] [Abstract][Full Text] [Related]
28. Comparing Onset of Biosimilar Versus Generic Competition in the United States.
Beall RF; Ronksley PE; Wick J; Darrow JJ; Sarpatwari A; Kesselheim AS
Clin Pharmacol Ther; 2020 Dec; 108(6):1308-1314. PubMed ID: 32621540
[TBL] [Abstract][Full Text] [Related]
29. Financial costs associated with monopolies on biologic medicines in Australia.
Gleeson D; Townsend B; Lopert R; Lexchin J; Moir H
Aust Health Rev; 2019 Feb; 43(1):36-42. PubMed ID: 29116927
[TBL] [Abstract][Full Text] [Related]
30. Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans.
Fischer MA; Avorn J
Health Serv Res; 2003 Aug; 38(4):1051-63. PubMed ID: 12968816
[TBL] [Abstract][Full Text] [Related]
31. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
32. Are drug prices subject to creative destruction? Evidence from the US, 1997-2017.
Lichtenberg FR
Health Econ; 2021 Aug; 30(8):1910-1932. PubMed ID: 33987916
[TBL] [Abstract][Full Text] [Related]
33. Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit.
Sheingold S; Nguyen NX
Medicare Medicaid Res Rev; 2014; 4(1):. PubMed ID: 24918023
[TBL] [Abstract][Full Text] [Related]
34. Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022.
Rome BN; Nagar S; Egilman AC; Wang J; Feldman WB; Kesselheim AS
JAMA Health Forum; 2023 Jan; 4(1):e225218. PubMed ID: 36705916
[TBL] [Abstract][Full Text] [Related]
35. High prices for generics in Australia - more competition might help.
Bulfone L
Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
[TBL] [Abstract][Full Text] [Related]
36. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.
Haas JS; Phillips KA; Gerstenberger EP; Seger AC
Ann Intern Med; 2005 Jun; 142(11):891-7. PubMed ID: 15941695
[TBL] [Abstract][Full Text] [Related]
37. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
Levy MS
Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
[TBL] [Abstract][Full Text] [Related]
38. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
39. Economic Burden Associated With Extended-Release vs Immediate-Release Drug Formulations Among Medicare Part D and Medicaid Beneficiaries.
Sumarsono A; Sumarsono N; Das SR; Vaduganathan M; Agrawal D; Pandey A
JAMA Netw Open; 2020 Feb; 3(2):e200181. PubMed ID: 32108893
[TBL] [Abstract][Full Text] [Related]
40. Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab.
Socal MP; Ezebilo I; Bai G; Anderson GF
Am J Health Syst Pharm; 2021 Jan; 78(3):216-221. PubMed ID: 33289035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
